Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient

Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient

Acute myeloid leukemia (AML) with inversion of chromosome 3 is characterized by overexpression of EVI1 and carries a dismal prognosis. Arsenic-containing compounds have been described to be efficacious in malignancies overexpressing EVI1. Here, we describe a case of AML with inv(3)(q21q26.2) treated...

Full description

Bibliographic Details
Main Authors:	Nielsen, Torsten H., Johnson, Nathalie, Garnier, Nicolas, Kwan, Stanley, Yao, Lu, Cocolakis, Eftihia, Hébert, Josée, Morgan, Robert A., Paquet, Éric, Callahan, Kevin P., Jordan, Craig T., Assouline, Sarit, Miller, Wilson H., Mann, Koren K.
Format:	Online
Language:	English
Published:	Frontiers Media S.A. 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570070/

Similar Items

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
by: Assouline, Sarit, et al.
Published: (2012)

Dimethylarsinothioyl Glutathione as a Metabolite in Human Multiple Myeloma Cell Lines upon Exposure to Darinaparsin
by: Yehiayan, Lucy, et al.
Published: (2014)

Darinaparsin Is a Multivalent Chemotherapeutic Which Induces Incomplete Stress Response with Disruption of Microtubules and Shh Signaling
by: Mason, Twila A., et al.
Published: (2011)

STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML
by: Oancea, Claudia, et al.
Published: (2014)

Targeting glutamine uptake in AML
by: Jacque, Nathalie, et al.
Published: (2014)

MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients
by: Bhise, Neha S., et al.
Published: (2016)

Arsenic Trioxide Overcomes Rapamycin-Induced Feedback Activation of AKT and ERK Signaling to Enhance the Anti-Tumor Effects in Breast Cancer
by: Guilbert, Cynthia, et al.
Published: (2013)

Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies
by: Batist, Gerald, et al.
Published: (2011)

The Challenge of AML in Older Patients
by: Burnett, Alan K
Published: (2013)

AML treatment in older adults
by: Sehgal, Alison, et al.
Published: (2015)

The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML
by: Pastore, Friederike, et al.
Published: (2014)

IRAK1: oncotarget in MDS and AML
by: Beverly, Levi J., et al.
Published: (2014)

Rational Combinations of Targeted Agents in AML
by: Bose, Prithviraj, et al.
Published: (2015)

Aberrant splicing and drug resistance in AML
by: de Necochea-Campion, Rosalia, et al.
Published: (2016)

A risk‐based approach to AML
by: Jos, de Wit
Published: (2007)

AML compliance in the age of individual accountability
by: Carlton, Greene, et al.
Published: (2017)

Arsenic and Diabetes
by: Smith, Allan H.
Published: (2013)

Arsenic in Beer
by: Bampton, A. H.
Published: (1901)

How mRNA is misspliced in acute myelogenous leukemia (AML)?
by: Mohamed, Aminetou Mint, et al.
Published: (2014)

Arsenic in Food
by: Bagchi, K. N., et al.
Published: (1941)

Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
by: Zuo, Zhuang, et al.
Published: (2012)

MicroRNAs Distinguish Cytogenetic Subgroups in Pediatric AML and Contribute to Complex Regulatory Networks in AML-Relevant Pathways
by: Daschkey, Svenja, et al.
Published: (2013)

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation
by: Federzoni, Elena A., et al.
Published: (2014)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
by: Webersinke, G, et al.
Published: (2014)

PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML
by: Verbiest, Tom, et al.
Published: (2015)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
by: Tettamanti, Sarah, et al.
Published: (2014)

CHEMOPATHOLOGICAL STUDIES WITH COMPOUNDS OF ARSENIC : II. HISTOLOGICAL CHANGES IN ARSENIC KIDNEYS.
by: Pearce, Louise, et al.
Published: (1915)

CHEMOPATHOLOGICAL STUDIES WITH COMPOUNDS OF ARSENIC : I. TYPES OF THE ARSENIC KIDNEY.
by: Pearce, Louise, et al.
Published: (1915)

CHEMOPATHOLOGICAL STUDIES WITH COMPOUNDS OF ARSENIC : III. ON THE PATHOLOGICAL ACTION OF ARSENICALS ON THE ADRENALS.
by: Brown, Wade H., et al.
Published: (1915)

The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation
by: Zahreddine, Hiba Ahmad, et al.
Published: (2014)

Arsenic as a teratogenic agent.
by: Ferm, V H
Published: (1977)

AML/CFT Regulations : Balancing Security with Access
by: World Bank
Published: (2012)

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
by: Islam, M., et al.
Published: (2017)

Chromosomal rearrangements in acute myeloid leukemia (AML)
by: Belloni, E, et al.
Published: (2010)

HLX in AML: novel prognostic and therapeutic target
by: Pandolfi, Ashley, et al.
Published: (2012)

A new inducible model for t(8;21) AML
by: Mulloy, James C
Published: (2013)

SYK Regulates mTOR Signaling in AML
by: Carnevale, Julia, et al.
Published: (2013)

The sources of AML/СTF legislation: concept description
by: M M Proshunin
Published: (2008-12-01)

Clinical Results of Hypomethylating Agents in AML Treatment
by: Cruijsen, Marjan, et al.
Published: (2014)

Pediatric AML: From Biology to Clinical Management
by: de Rooij, Jasmijn D. E., et al.
Published: (2015)